|drug755||Lopinavir and Ritonavir Tablets Wiki||0.58|
|drug1351||Tap water Wiki||0.58|
|drug485||Essential oils Wiki||0.58|
|drug917||Normal saline Wiki||0.41|
|drug1658||standard care Wiki||0.41|
|D045169||Severe Acute Respiratory Syndrome NIH||0.10|
|D018352||Coronavirus Infections NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.06|
|D003141||Communicable Diseases NIH||0.06|
There are 3 clinical trials
The SARS-CoV-2 coronavirus pandemic is responsible for more than 180,000 deaths worldwide and 20,000 deaths in France. To date, no treatment or vaccine has been successful. Povidone-iodine is an antiseptic suitable for use on the skin and mucosa with potent virucidal activity, particularly against coronaviruses. It is marketed for oro-nasopharyngeal decolonization. 24 patients with positive nasopharyngeal SARS-CoV-2 carriage will be randomized (1:1) in an experimental group (benefiting from povidone iodine decolonization) or a control group. Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days. Patients will be followed for 7 days to evaluate the efficacy and safety of povidone iodine decolonization.
COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that is present in the nose and mouth. This also could mean that there is less virus available to pass on to others. We want to see if the use of nose rinses and mouth washes using Povidone-Iodine will reduce the the amount of virus in the nose and throat of people who have tested positive for COVID-19 disease and also reduce the spread of infection within their household.
Description: viral load as measured by real time polymerase chain reaction (PCR)Measure: Change in viral load in the oral and nasopharyngeal cavity Time: Day 0, 2, 3, 7, 14
Description: Visual analogue score 1-5 per symptom via a smartphone appMeasure: Symptom severity in primary participants and co-residents Time: Days 0 to 14
The purpose of this study is to assess the ability of regular gargling to eliminate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the throat and nasopharynx. This 4 arms interventional study compares the effect of gargling using povidone-iodine, essential oils- based, tap water with control (no intervention) among Stage 1 coronavirus disease-2019 (COVID-19) patients. Findings from this study will provide new insight into the importance of gargling in the treatment and prevention of COVID-19.
Description: Swabs from oropharynx and nasopharynx will be taken at day 4 and 6 of intervention.Measure: Early Viral Clearance Time: 6 days
Description: Swabs from oropharynx and nasopharynx will be taken at day 12Measure: Late viral clearance Time: 12 days
Description: Progression will be monitored by symptoms diary for 7 daysMeasure: Symptoms progression Time: 7 days
Description: Progression will be monitored by clinical data for 14 daysMeasure: Disease Progression Time: 14 days
Description: Progression will be monitored by laboratory data for 14 daysMeasure: Disease Progression 2 Time: 14 days